Medical Lovers Study Snaps

The Rationale for Dostarlimab Monotherapy In MSI-H and MSS Endometrial Cancer Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d’Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti–PD-1 monotherapy with dostarlimab in patients with microsatellite instability–hi...

Interpreting the Role of the Ramucirumab Plus Erlotinib Combination in EGFR+ NSCLC Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab plus erlotinib was compared to erlotinib plus placebo in patients...